COMPARE · Data as of August 28, 2026
ALLY vs SLM
Verdict: Side-by-side breakdown using the Bull Rankings model. ALLY scored 82.0, SLM scored 66.0 — ALLY leads.
Compare another set
ALLY
Ally Financial Inc.
66.6Fin
$42.18 · $12.8B
fundamentals as of
Strength gap
4.8
SLM leads
SLM
SLM Corporation
71.4Fin
$26.47 · $5.0B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthSLM+7.3%
- Largest discount to fair valueALLY-20%
Side by side · every name on one set of axes
Fundamentals, head-to-head
ALLY
SLM
$762mC+
FCF
-$325mF
-1.4%D+
Rev
+7.3%B
—
D/E
2.36C
9.9xA-
P/E
—
0.46A
PEG
0.51A-
—
P/S
3.0xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALLY
SLM
20% below
Price vs fair valuelower is cheaper
—
~8%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
-2%
1-yr DCF upside
—
+25%
5-yr DCF upside
—
+77%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
The companies
ALLYAlly Financial Inc.
Why now
Credit Services · market cap $12.8b. 11% off the 52-week high of $47.29. PEG 0.46 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $53.70 (implying +27% upside).
Moat
Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent.
Risk
Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
SLMSLM Corporation
Why now
Credit Services · market cap $5.0b. 17% off the 52-week high of $32.07. PEG 0.51 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $28.55 (implying +8% upside).
Moat
Net margin 44% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 30% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
D/E 2.36 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Free cash flow is negative (-$325m) — capital raises or debt issuance likely required; dilution / leverage risk. Balance-sheet financial — book value, net interest margin, and credit loss provisions are the lever points; a rates regime change or a deterioration in the loan book moves the stock more than EPS does.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.